NASDAQ:AKBA   Akebia Therapeutics, Inc.
Weekly Demand Zone
Entry 2.47
Stop 1.9
Target 5

Risk management is much more important than a good entry point.
The max Risk of each plan should be less than 1% of an account.
I am not a PRO trader. I trade option to test my trading plan with small cost.
Trade active:
Buy 2022 Jan C2.5/5 0.45 x4
No stop
Max RRR 4:1

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.